全文获取类型
收费全文 | 8194篇 |
免费 | 457篇 |
国内免费 | 102篇 |
专业分类
耳鼻咽喉 | 94篇 |
儿科学 | 132篇 |
妇产科学 | 136篇 |
基础医学 | 905篇 |
口腔科学 | 304篇 |
临床医学 | 654篇 |
内科学 | 2499篇 |
皮肤病学 | 105篇 |
神经病学 | 689篇 |
特种医学 | 321篇 |
外科学 | 1302篇 |
综合类 | 28篇 |
一般理论 | 1篇 |
预防医学 | 352篇 |
眼科学 | 69篇 |
药学 | 450篇 |
中国医学 | 8篇 |
肿瘤学 | 704篇 |
出版年
2024年 | 15篇 |
2023年 | 140篇 |
2022年 | 274篇 |
2021年 | 503篇 |
2020年 | 287篇 |
2019年 | 337篇 |
2018年 | 376篇 |
2017年 | 260篇 |
2016年 | 306篇 |
2015年 | 318篇 |
2014年 | 428篇 |
2013年 | 472篇 |
2012年 | 670篇 |
2011年 | 586篇 |
2010年 | 334篇 |
2009年 | 326篇 |
2008年 | 440篇 |
2007年 | 412篇 |
2006年 | 373篇 |
2005年 | 307篇 |
2004年 | 241篇 |
2003年 | 217篇 |
2002年 | 175篇 |
2001年 | 75篇 |
2000年 | 69篇 |
1999年 | 58篇 |
1998年 | 42篇 |
1997年 | 27篇 |
1996年 | 32篇 |
1995年 | 33篇 |
1994年 | 24篇 |
1992年 | 35篇 |
1991年 | 39篇 |
1990年 | 39篇 |
1989年 | 56篇 |
1988年 | 30篇 |
1987年 | 43篇 |
1986年 | 32篇 |
1985年 | 37篇 |
1984年 | 21篇 |
1983年 | 17篇 |
1980年 | 16篇 |
1979年 | 32篇 |
1978年 | 21篇 |
1977年 | 21篇 |
1974年 | 18篇 |
1973年 | 14篇 |
1972年 | 18篇 |
1971年 | 14篇 |
1970年 | 13篇 |
排序方式: 共有8753条查询结果,搜索用时 15 毫秒
1.
2.
Thiazolidinediones (TZDs), agonists of the nuclear receptor peroxisome proliferator-activated receptor-γ, induce the expression
of many genes, including several enzymes and transporters involved in glucose and lipid metabolism. Although the efficacy
of TZDs on blood glucose control in type 2 diabetes is not questionable, their cardiovascular effects have been debated, with
beneficial or harmful actions suggested by different authors. This article reviews the available clinical evidence on the
cardiovascular effects of TZDs, discussing possible mechanisms underlying the observed effects and suggesting some directions
for future research. 相似文献
3.
Francesco Landi Ettore Capoluongo Andrea Russo Graziano Onder Matteo Cesari Paola Lulli Angelo Minucci Marco Pahor Cecilia Zuppi Roberto Bernabei 《Growth hormone & IGF research》2007,17(1):58-66
CONTEXT: Increasing evidences from experimental and human studies suggest that the activity of the growth hormone (GH/insulin-like growth factor-I) axis may contribute to the age-related cognitive decline and poor cognition in late life. OBJECTIVE: The aim of the present study was to evaluate the relationship of total serum free IGF-I and its binding protein-3 with cognitive performance in older persons aged 80 years or older. DESIGN: Data are from baseline evaluation of the ilSIRENTE study (n=353). Cognitive performance was evaluated using five items enclosed in the Minimum Data Set for Home Care assessment form: short-term memory, procedural memory, cognitive skills in daily decision making, verbal expression, comprehension. Free insulin-like growth factor-I (free IGF-I) and IGF-binding protein-3 (IGFBP-3) in blood were measured. Analysis of covariance (ANCOVA) was used to examine the relationship between cognitive impairment and the serum free IGF-I and IGFBP-3 concentrations, after adjustment for potential confounding variables. RESULTS: After adjustment for potential confounders, which included age, gender, education, cerebrovascular disease, ischemic heart disease, congestive heart failure, hypertension, diabetes, depression, Parkinson diseases, thyroid diseases, smoking status, alcohol abuse, body mass index, and number of medications, individuals with verbal expression problems (n=20) and individuals with comprehension problems (n=24) had a significantly lower serum levels of readily dissociable IGF-I than participants without cognitive impairments. The serum IGFBP-3 presented the same behavior of free IGF-I. CONCLUSION: The present study suggests that among old-old subjects living in the community lower levels of total serum free IGF-I and IGFBP-3 are associated with impairment of cognitive performance. This finding suggests that the GH/IGF-I axis may play an important role in the age-related decline of cognitive performance. 相似文献
4.
A Bortolotti D Castelli D Verotta M Bonati 《European journal of drug metabolism and pharmacokinetics》1989,14(2):145-151
The pharmacokinetic and pharmacodynamic profiles of metoprolol were studied in adult male rabbits given 3.2 mg/kg i.v. before and during liver failure. The partition of metoprolol between blood cells and plasma averaged 1.14 in both conditions. Plasma protein binding, concentration-independent, was 32% and 17% in normal and pathological status, respectively. With normal liver function the terminal elimination half-life for the drug was 0.54-0.96 h, rising to 1.0-2.1 h in liver failure. Differences of the same order were observed for total plasma drug clearance (average 3.7 vs 1.5 1/h/kg), MRT (0.77 vs 1.92 h), AUC (0.9 vs 2.2 mg h/l) and k10 (3.17 vs 1.80 h-1). Liver impairment did not affect the volume of distribution of the central compartment, the steady-state volume of distribution and the other intercompartmental rate constants. Although metoprolol was eliminated in the urine, the amount excreted was low (1.5% of the administered dose) in both conditions. The pharmacokinetic model was extended by an 'effect compartment', which has no influence on the predetermined mass of drug in the body, to analyse the relationship between heart rate fall and changes in metoprolol plasma concentrations. After drug administration, heart rate fell rapidly about 90 beats in both states. The mean unbound plasma concentration producing 50% of this reduction was double during liver failure compared to normal condition (0.03 vs 0.07 mg/l), but the temporal aspects of drug equilibration with site of action were similar. 相似文献
5.
6.
Endovascular repair for concomitant multilevel aortic disease. 总被引:2,自引:0,他引:2
Patrizio Castelli Roberto Caronno Gabriele Piffaretti Matteo Tozzi Chiara Lomazzi Domenico Laganà Gianpaolo Carrafiello Salvatore Cuffari 《European journal of cardio-thoracic surgery》2005,28(3):478-482
OBJECTIVE: Patients with multilevel aortic disease represent a small subgroup with the need for extensive surgical treatment at considerable risk. We present our experience of endovascular exclusion for simultaneous thoracic and abdominal aortic disease in four patients. METHODS: Between January 2002 and January 2005, four patients underwent endovascular repair for simultaneous thoracic and abdominal aortic disease. Mean age was 69+/-10 years (range, 60-81). Thoracic lesions included penetrating aortic ulcer (n=2, ruptured=1), atherosclerotic aneurysm (n=1), and chronic type B dissection (n=1). Abdominal aortic disease included atherosclerotic infrarenal (n=3) and juxtarenal (n=1) aortic aneurysms. Thoracic aortic stent-grafts had been the following: Excluder/TAG (n=3) or Talent (n=1) straight tube devices. Abdominal aortic stent-grafts used were as following: Excluder (n=3) or Zenith (n=1). All patients were followed-up with CT-angiography and chest X-rays 1, 4, 12 months after the procedure, and once per year thereafter. RESULTS: Stent-graft deployment was technically successful in all cases. Intraoperative mortality was not observed. Mean procedure time was 94+/-34 min (range, 70-145). Early postoperative complications occurred in one patient that developed acute renal failure but dialysis was not required. Mean hospitalisation was 8+/-5 days (range, 4-15). Late death occurred in one patient for an undetected ruptured thoracic type 1 endoleak. All three survivors are currently well 16.5 months (range, 3-36) after surgery. No neurological complications developed. CONCLUSION: Simultaneous abdominal and thoracic endovascular repair for multilevel aortic disease is feasible and could be a viable alternative in high-risk patients, who otherwise may not be suitable candidates for conventional repair. 相似文献
7.
8.
D. M. F. Edwards C. Pellizzoni H. P. Breuel A. Berardi M. G. Castelli E. Frigerio I. Poggesi M. Rocchetti A. Dubini M. Strolin Benedetti 《Biopharmaceutics & drug disposition》1995,16(6):443-460
The pharmacokinetics of reboxetine, a new antidepressant agent, were found to be close to linear in a crossover study comparing administration of single 2, 3, 4 and 5 mg capsule doses in 15 healthy male volunteers, and in the same study the capsules were bioequivalent to the proposed therapeutic tablet formulation (4mg). Kinetic analysis was based on HPLC assay of reboxetine in plasma and urine collected up to 72 h after each administration. Plasma levels indicated a rapid absorption (tmax?2h) and an elimination half-life of about 13 h. Clearance and volume of distribution were modest (ratios to bioavailability: CL/F?29 mL min?1; Vz/F?32L); urinary excretion was ~9% of dose, corresponding to a renal clearance of only 3 mL min?1 (a value consistent with the rate of glomerular filtration of unbound drug). In vitro, binding to plasma proteins, estimated from radioactivity levels following dialysis of 14C-labelled reboxetine, appeared to be dominated by α1-acid glycoprotein without marked saturation up to plasma concentrations of over 500 ng mL?1 (2.8–3.1% unbound with human plasma from three additional volunteers; 1.8–2.0% for 2gL?1 orosomucoid α1-acid glycoprotein, and 46.4–47.4% for 40 gL?1 albumin), whilst the mean Cmax in the current study was much lower (164 ng mL?1 after a 5 mg dose). 相似文献
9.
Paolo Cossu Rocca Matteo Brunelli Stefano Gobbo Albino Eccher Emma Bragantini Maria M Mina Vincenzo Ficarra Filiberto Zattoni Alberto Zamò Maurizio Pea Aldo Scarpa Marco Chilosi Fabio Menestrina Franco Bonetti John N Eble Guido Martignoni 《Modern pathology》2007,20(7):722-728
S100A1 is a calcium-binding protein, which has been recently found in renal cell neoplasms. We evaluated the diagnostic utility of immunohistochemical detection of S100A1 in 164 renal cell neoplasms. Forty-one clear cell, 32 papillary, and 51 chromophobe renal cell carcinomas, and 40 oncocytomas, 164 samples of normal renal parenchyma adjacent to the tumors and 13 fetal kidneys were analyzed. The levels of S100A1 mRNA detected by quantitative RT-PCR analysis of frozen tissues from seven clear cell, five papillary, and six chromophobe renal cell carcinomas, four oncocytomas, and nine samples of normal renal tissues adjacent to neoplasms were compared with the immunohistochemical detection of protein expression. Clear cell and papillary renal cell carcinomas showed positive reactions for S100A1 in 30 out of 41 tumors (73%) and in 30 out of 32 (94%) tumors, respectively. Thirty-seven renal oncocytomas out of 40 (93%) were positive for S100A1, whereas 48 of 51 (94%) chromophobe renal cell carcinomas were negative. S100A1 protein was detected in all samples of unaffected and fetal kidneys. S100A1 mRNA was detected by RT-PCR in all normal kidneys and renal cell neoplasms, although at very different levels. Statistical analyses comparing the different expression of S100A1 in clear cell and chromophobe renal cell carcinomas observed by immunohistochemical and RT-PCR methods showed significant values (P<0.001), such as when comparing by both techniques the different levels of S100A1 expression in chromophobe renal cell carcinomas and oncocytomas (P<0.001). Our study shows that S100A1 protein is expressed in oncocytomas, clear cell and papillary renal cell carcinomas but not in chromophobe renal cell carcinomas. Its immunodetection is potentially useful for the differential diagnosis between chromophobe renal cell carcinoma and oncocytoma. Further, S100A1 protein expression is constantly detected in the normal parenchyma of the adult and fetal kidney. 相似文献
10.